Evidence map›Paper›PMID 41338587›Full record

ReviewGeriatrics & gerontology international2026

Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale.

Masaki Mogi, Shuang Liu, Yasuyuki Suzuki, Yuuka Shibata, Shizuo Yamada

Abstract readReview
In one paragraph

Review in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masaki MogiDepartment of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan.
Shuang LiuDepartment of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan.ORCID https://orcid.org/0000-0002-6401-7317
Yasuyuki SuzukiDepartment of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan.
Yuuka ShibataCenter for Pharmacist Education, School of Pharmacology, Nihon University, Chiba, Japan.
Shizuo YamadaCenter for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Science, University of Shizuoka, Shizuoka, Japan.ORCID https://orcid.org/0000-0002-5915-9863

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy. One year has passed since the "Japanese Anticholinergic Risk Scale" was published by the Japanese Society of Geriatric Pharmacy, and the anticholinergic effects of various medications have garnered attention. These medications are used in clinical practice and research. The anticholinergic effects of drugs are not necessarily induced solely by binding to muscarinic receptors and exerting antagonistic actions but may also occur as a result of various combined effects. In this review, we focus on drugs that show differences between the "Yamada Classification," which was created based on in vitro muscarinic receptor binding activity, and the "Japanese Anticholinergic Risk Scale." We re-examine anticholinergic effects and, through a review of the literature, identify drugs that induce "anticholinergic-like effects" beyond direct muscarinic receptor antagonism. By understanding the potential mechanisms underlying "anticholinergic-like effects" in drugs where anticholinergic effects listed in the risk scale are not anticipated, we aim to reemphasize the prevalence of drugs with anticholinergic-like effects.

Indexed as

Cholinergic AntagonistsAgedHumansJapanPolypharmacyReceptors, MuscarinicRisk AssessmentCholinergic AntagonistsReceptors, Muscarinicanticholinergic burdenanticholinergic‐like effectscognitive impairmentJapanese Anticholinergic Risk Scalemuscarinic receptor antagonism

Identifiers

PMID41338587
PMCPMC12811049

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.